In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 × 1010 colony-forming units

Vaccine

Volumn 28, Issue 20, 2010, Pages 3602-3608

  Lyon, C E ^a   Sadigh, K S ^a   Carmolli, M P ^a   Harro, C ^b   Sheldon, E ^c   Lindow, J C ^a   Larsson, C J ^a   Martinez, T ^c   Feller, A ^b   Ventrone, C H ^a   Sack, D A ^b   DeNearing, B ^b   Fingar, A ^a   Pierce, K ^a   Dill, E A ^a   Schwartz, H I ^c   Beardsworth, E E ^a   Kilonzo, B ^a   May, J P ^d   Lam, W ^d   Upton, A ^d   Budhram, R ^d   Kirkpatrick, B D ^a   more..

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MIAMI RESEARCH ASSOCIATES   (United States)

^d Emergent Biosolutions   (United Kingdom)

Author keywords

Oral vaccine; Typhoid; Typhoid vaccine

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLACEBO; TYPHOID VACCINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASTHENIA; BACTEREMIA; CHILL; CLINICAL TRIAL; COHORT ANALYSIS; COLONY FORMING UNIT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IMMUNOGENICITY; MALE; METHODOLOGY; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA TYPHI; SEROCONVERSION; SEROLOGY; SINGLE DRUG DOSE; TYPHOID FEVER;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 77950595802     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.017     Document Type: Article

References (25)

1. Crump J. The global burden of typhoid fever. Bull World Health Org 82 5 (2004) 346-353
2. Fraser A., Paul M., Goldberg E., Acosta C.J., and Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 25 45 (2007) 7848-7857
3. Engels E.A., Falagas M.E., Lau J., and Bennish M.L. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316 7125 (1998) 110-116
4. Wain J., Hoa N.T., Chinh N.T., et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25 6 (1997) 1404-1410
5. DeRoeck D., Jodar L., and Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med 357 11 (2007) 1069-1071
6. Parry C.M., Hien T.T., Dougan G., White N.J., and Farrar J.J. Typhoid fever. N Engl J Med 347 22 (2002) 1770-1782
7. Hohmann E.L., Oletta C.A., Killeen K.P., and Miller S.I. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 173 6 (1996) 1408-1414
8. Tacket C.O., Pasetti M.F., Sztein M.B., Livio S., and Levine M.M. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 190 3 (2004) 565-570
9. Wahid R., Salerno-Goncalves R., Tacket C.O., Levine M.M., and Sztein M.B. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25 8 (2007) 1416-1425
10. Kirkpatrick B.D., McKenzie R., O'Neill J.P., et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24 (2006) 116-123
11. Kirkpatrick B.D., Tenney K.M., Larsson C.J., et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 192 3 (2005) 360-366
12. Hindle Z., Chatfield S.N., Phillimore J., et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 70 7 (2002) 3457-3467
13. Kirkpatrick B.D., McKenzie R., O'Neill J.P., et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24 (2006) 116-123
14. Cedzynski M., Szemraj J., Swierzko A.S., et al. Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system. Clin Exp Immunol 136 2 (2004) 304-311
15. Khan S.A., Stratford R., Wu T., et al. Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. Vaccine 21 5-6 (2003) 538-548
16. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 8 4 (1990) 321-326
17. Kantele A., Arvilommi H., and Jokinen I. Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi. J Infect Dis 153 6 (1986) 1126-1131
18. Baqar S., Nour El Din A.A., Scott D.A., et al. Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Clin Diagn Lab Immunol 4 3 (1997) 375-379
19. Salerno-Goncalves R., Wahid R., and Sztein M.B. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect Immun 73 6 (2005) 3521-3530
20. Levine M.M. Typhoid fever vaccines. In: Plotkin S., Orenstein W.A., and Offit P.A. (Eds). Vaccines. fifth ed. (2008), Elsevier, Amsterdam 888-914
21. Black R., Levine M.M., Young C., et al. Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules. Dev Biol Stand 53 (1983) 9-14
22. Levine M.M., Ferreccio C., Black R.E., Tacket C.O., and Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 11 Suppl. 3 (1989) S552-S567
23. Tacket C.O., Ferreccio C., Robbins J.B., et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 154 2 (1986) 342-345
24. Sur D., Lopez A.L., Kanungo S., et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374 9702 (2009) 1694-1702
25. Keitel W.A., Bond N.L., Zahradnik J.M., Cramton T.A., and Robbins J.B. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12 3 (1994) 195-199